Currently, there are 59.52M common shares owned by the public and among those 56.09M shares have been available to trade.
The company’s stock has a 5-day price change of 0.57% and -21.64% over the past three months. PTGX shares are trading -4.61% year to date (YTD), with the 12-month market performance up to 49.13% higher. It has a 12-month low price of $23.17 and touched a high of $48.89 over the same period. PTGX has an average intraday trading volume of 670.57K shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -4.36%, -10.38%, and -2.84% respectively.
Institutional ownership of Protagonist Therapeutics Inc (NASDAQ: PTGX) shares accounts for 100.83% of the company’s 59.52M shares outstanding.
It has a market capitalization of $2.19B and a beta (3y monthly) value of 2.23. The stock’s trailing 12-month PE ratio is 13.81, while the earnings-per-share (ttm) stands at $2.67. Price movements for the stock have been influenced by the stock’s volatility, which stands at 4.87% over the week and 4.24% over the month.
Earnings per share for the fiscal year are expected to increase by 270.31%, and -154.72% over the next financial year.
Looking at the support for the PTGX, a number of firms have released research notes about the stock. Goldman stated their Neutral rating for the stock in a research note on December 06, 2024, with the firm’s price target at $47. BMO Capital Markets coverage for the Protagonist Therapeutics Inc (PTGX) stock in a research note released on December 06, 2024 offered a Outperform rating with a price target of $62. Wedbush was of a view on November 05, 2024 that the stock is Outperform, while TD Cowen gave the stock Buy rating on September 24, 2024, issuing a price target of $65. Truist on their part issued Buy rating on September 09, 2024.
